March 1, 2023
In March 2023, the three major insulin manufacturers (Eli Lilly, Novo Nordisk, and Sanofi) reduced the
list prices of several brand insulins, effective in 4Q 2023 (Lilly)
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
News
March 1, 2023
March 1, 2023 - Eli Lilly announced the price of Rezvoglar (insulin glargine-aglr) as well as price cuts on
other insulin products and a cap on out-of-pocket (OOP) costs for insulin.
February 28, 2023
February 28, 2023 – Reata Pharmaceuticals, Inc., a biopharmaceutical company focused on developing
and commercializing novel therapies for patients with severe diseases
February 23, 2023
February 23, 2023 - Global Pharma Healthcare is voluntarily recalling Batch No. H29 of Artificial Eye
Ointment, distributed by Delsam Pharma
February 23, 2023
February 23, 2023 – The FDA has approved AltuviiioTM (Sanofi) [Antihemophilic Factor (Recombinant), Fc-
VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog
February 22, 2023
February 22, 2023 - Pfizer Inc. has announced that the U.S. Food and Drug Administration has granted
Priority Review for the company’s Biologics License Application (BLA) for elranatamab
February 21, 2023
February 21, 2023 - Regeneron Pharmaceuticals, Inc. has announced the U.S. Food and Drug
Administration has accepted for Priority Review the Biologics License
February 17, 2023
February 17, 2023 - Travere Therapeutics, Inc. has announced that the U.S. Food and Drug Administration has granted accelerated approval to FilspariTM